Gesundheit25.09.2026@HealthDesk
Task Force Tells All US Women to Start Mammograms at 40
United States Preventive Services Task ForceAgency for Healthcare Resource and Quality, 5600, Fishers Lane, Spring Lake Park, Rockville, Montgomery County, Maryland, 20857, United States
Beginnt am 30.04.2024BESTÄTIGT 89 % SICHERHEITvor 2,4 JahrenThe Task Force announcement opens "April 30, 2024 - The U.S. Preventive Services Task Force released today a final recommendation statement on screening for breast cancer^[4]".
The US Preventive Services Task Force finalises its advice that all women get a mammogram every other year from age 40 to 74, lowering the start age from 50.
0.71
Gesundheit25.09.2026@HealthDesk
FDA Approves First HRT Labels Without the Breast Cancer Boxed Warning
U.S. Food and Drug AdministrationMahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United States
Beginnt am 12.02.2026BESTÄTIGT 84 % SICHERHEITvor 225 TagenThe FDA^[1][4] news release is headed "For Immediate Release: February 12, 2026" and says the FDA "has approved drug labeling changes to six menopausal hormone therapy products".
The FDA approves new labels for six menopausal hormone therapy products, one from each class, that drop the cardiovascular, breast cancer and dementia statements from the boxed warning; 29 companies have filed changes.
0.71
Gesundheit25.09.2026@HealthDesk
HHS and FDA Move to Strip Boxed Warnings From Menopause Hormone Therapy
U.S. Food and Drug AdministrationU.S. Department of Health and Human Services, 200, Independence Avenue Southwest, Ward 6, Washington, District of Columbia, 20201, United States
Beginnt am 10.11.2025 16:09BESTÄTIGT 86 % SICHERHEITvor 319 TagenThe FDA^[1][3] news release is headed "For Immediate Release: November 10, 2025" and says Kennedy and Makary "made the announcement at a press conference at HHS"; CBS News' livestream of it began at 16:09 UTC.
At an HHS press conference, Robert F. Kennedy Jr. and FDA Commissioner Marty Makary announce that the FDA will remove the breast cancer, heart disease and dementia boxed warnings that have covered menopausal hormone therapy since the early 2000s.
0.69
Gesundheit25.09.2026@HealthDesk
FDA Decision Due on Roche's Giredestrant for Early Breast Cancer
RocheMahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United States
Beginnt am 30.11.2026GEPLANT 78 % SICHERHEITin 66 TagenRoche's^[1] release says "The FDA is expected to make a decision on the approval by 30 November 2026", the PDUFA goal date set under Priority Review.
The FDA is due to decide by 30 November 2026 whether to approve Roche's giredestrant, an oral SERD that cut the risk of recurrence or death by 30% versus standard hormone therapy in early ER-positive breast cancer.
0.67
Recht25.09.2026@LawDesk
Fifth Circuit Reinstates In-Person Dispensing for Mifepristone
United States Court of Appeals for the Fifth CircuitUnited States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United States
Beginnt am 01.05.2026BESTÄTIGT 82 % SICHERHEITvor 147 TagenThe opinion in No. 26-30203 is stamped "FILED May 1, 2026" and orders that "the motion to stay the 2023 REMS under 5 U.S.C. § 705 pending appeal is GRANTED".^[1]
A Fifth Circuit panel granted Louisiana a stay of the FDA's 2023 mifepristone rules, ending telehealth prescribing and mail or pharmacy dispensing of the abortion pill nationwide until the Supreme Court stepped in.
0.66
Gesundheit23.09.2026@HealthDesk
FDA genehmigt Abbotts Glukose-Keton-Sensor Libre Duo
Abbott Laboratories1360 South Loop Road, Alameda, Alameda County, California, 94502, United States
Beginnt am 25.08.2026BESTÄTIGT 87 % SICHERHEITvor 31 TagenDie Mitteilung trägt die Datumszeile „ABBOTT PARK, Illinois, 25. Aug. 2026“ und besagt, Abbott habe „heute die Genehmigung seines Systems Libre Duo 10 Day durch die US-Arzneimittelbehörde FDA^[2][3] bekanntgegeben“; der De-Novo-Eintrag der FDA nennt dasselbe Entscheidungsdatum, den 25.08.2026.
Die FDA hat Abbotts Libre Duo 10 Day genehmigt, das erste Wearable, das sowohl Glukose als auch Ketone kontinuierlich misst und Menschen mit Diabetes ab 2 Jahren vor einer diabetischen Ketoazidose vor steigenden Ketonwerten warnt.
0.64
Recht25.09.2026@LawDesk
Supreme Court Restores Mail Access to Mifepristone in Louisiana Case
Supreme Court of the United StatesSupreme Court of the United States, 1, 1st Street Northeast, Ward 6, Washington, District of Columbia, 20543, United States
Beginnt am 14.05.2026BESTÄTIGT 84 % SICHERHEITvor 134 TagenThe order in Nos. 25A1207 and 25A1208 is dated "[May 14, 2026]" and says "The applications for stay ... are granted".^[1]
The Supreme Court stayed the Fifth Circuit's order in Louisiana v. FDA, so mifepristone can again be prescribed by telehealth and sent by mail while the case goes on; Justices Thomas and Alito dissented.
0.63
Gesundheit23.09.2026@HealthDesk
Lilly reicht Retatrutid bei der FDA zur Zulassung ein
Eli LillyEli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Beginnt am 31.03.2027GESCHÄTZT3 Monate verspätet77 % SICHERHEITin 187 TagenLilly „plant, Retatrutid anschließend im ersten Quartal 2027 zur Zulassung in den USA einzureichen“ – ein Tag wird nicht genannt, daher liegt der Pin auf dem letzten Tag des ersten Quartals 2027.^[1]
Lilly will den Zulassungsantrag für das Biologikum (BLA) Retatrutid, die Dreifach-Hormon-Spritze gegen Adipositas, die in Phase 3 das Gewicht um bis zu 28,3 Prozent senkte, im ersten Quartal 2027 bei der FDA einreichen, sobald das Datenpaket zur Herstellung vollständig ist.
0.63
Recht25.09.2026@LawDesk
Supreme Court Rejects Challenge to Mifepristone in FDA v. Alliance
Supreme Court of the United StatesSupreme Court of the United States, 1, 1st Street Northeast, Ward 6, Washington, District of Columbia, 20543, United States
Beginnt am 13.06.2024BESTÄTIGT 84 % SICHERHEITvor 2,3 JahrenThe slip opinion in No. 23-235 is headed "Argued March 26, 2024—Decided June 13, 2024".^[1]
A unanimous Supreme Court threw out anti-abortion doctors' challenge to the FDA's rules for the abortion pill mifepristone, holding they had no standing to sue, so mail and telehealth access stayed in place.
0.62
Gesundheit25.09.2026@HealthDesk
FDA Puts a Boxed Liver-Injury Warning on Menopause Drug Veozah
Astellas PharmaMahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United States
Beginnt am 16.12.2024BESTÄTIGT 87 % SICHERHEITvor 1,8 JahrenThe FDA^[1][5] drug safety communication carries the entry "12-16-2024 Update: FDA adds a Boxed Warning, our most prominent warning, to highlight the known risk of rare but serious liver injury".
The FDA adds a boxed warning, its most prominent, to Astellas' hot-flash pill Veozah after a patient suffered serious liver injury within about 40 days of starting it, and orders monthly liver tests for the first months.
0.62
Recht25.09.2026@LawDesk
Fifth Circuit Hears Louisiana's Appeal Against Mail-Order Mifepristone
United States Court of Appeals for the Fifth CircuitUnited States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United States
Beginnt am 09.09.2026BESTÄTIGT 83 % SICHERHEITvor 16 TagenThe court's recording of 26-30203 State of Louisiana v. FDA gives "Hearing Date: Wednesday, September 9, 2026 Courtroom: En Banc Courtroom".^[1]
A Fifth Circuit panel of Judges Richman, Higginson and Douglas heard Louisiana's bid to end telehealth prescribing of mifepristone and pressed the state hard on whether it has standing to sue.
0.61
Gesundheit23.09.2026@HealthDesk
FDA lässt Abbotts Volt-PFA-System gegen Vorhofflimmern zu
Abbott LaboratoriesAbbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Beginnt am 22.12.2025BESTÄTIGT 84 % SICHERHEITvor 277 TagenDie Mitteilung trägt die Ortsangabe "ABBOTT PARK, Ill., 22. Dezember 2025" und besagt, Abbott habe "heute bekannt gegeben", dass die FDA^[5] das Volt PFA System zugelassen hat (der FDA-Eintrag selbst nennt als Entscheidungsdatum den 19.12.2025).
Die FDA hat Abbotts Pulsed-Field-Ablationssystem Volt zugelassen – einen Ballon-im-Korb-Katheter, der kartiert, stimuliert und abladiert – zur Behandlung von paroxysmalem und persistierendem Vorhofflimmern. Grundlage war die VOLT-AF-IDE-Studie mit 392 Patienten an 40 Zentren.
0.61

The FDA^[1] page says "Enforcement of the MQSA regulations as amended by the 2023 MQSA Final Rule began on September 10, 2024"; the rule has no end date, so the period is open-ended.

Beginn: 10. Sept. 202490 % SICHERHEITlaut der Quelle

FDA Rule Requiring Breast Density Notices With Every Mammogram Takes Effect

Every US mammography facility must now tell patients in writing whether their breast tissue is dense, which can hide cancers on a mammogram, under the FDA's amended Mammography Quality Standards Act rule.

From 10 September 2024 the FDA began enforcing its amended Mammography Quality Standards Act rules, issued on 10 March 2023^[1][4]
Every patient's lay summary must now say whether her breast tissue is dense or not dense, in one of two federally worded statements^[1][3]
The dense statement explains that dense tissue makes cancer harder to find on a mammogram, raises the risk of breast cancer, and that other imaging may help^[1]
Reports to doctors must classify density in one of four categories and give an overall final assessment^[1]
Suspicious or highly suggestive results must reach the patient within 7 calendar days of interpretation^[1]

@HealthDesk

Belege 489 % SICHERHEIT

Der erste Eintrag ist immer die Quelle des Pins. Die Gesamtsicherheit ist ein gewichteter Durchschnitt, wie fest jeder Beleg die oben verwendeten Start- und Endzeiten stützt; ein Beleg zählt für je 180 Tage, die er älter ist als der neueste, nur halb so viel.

[1]90%
fda.gov/radiation-emitting-products/mammography-quality-standards-act-mqsa-and-mqsa-program/important-information-final-rule-amend-mammography-quality-standards-act-mqsa
fda.gov· Gepostet am 25. Sept. 2026· Beginn 10. Sept. 2024 ✓· 90 % der Wertung
The FDA page says "Enforcement of the MQSA regulations as amended by the 2023 MQSA Final Rule began on September 10, 2024"; the rule has no end date, so the period is open-ended.
[2]70%
FDA updates mammography regulations to require breast density reporting (CBS New York)
youtube.com· Veröffentlicht am 4. Sept. 2024· 5 % der Wertung
Susan G. Komen's Valerie Nelson on the new federal density reporting rule days before it took effect.^[1]
[3]80%
Federal: FDA Dense Breast Reporting (DenseBreast-info)
densebreast-info.org· Veröffentlicht am 12. Aug. 2024· 5 % der Wertung
Beginning 10 September 2024, facilities must give every patient one of two federal breast density statements, and the report to the referring provider must assess density.^[1]
[4]90%
Mammography Quality Standards Act (final rule, 88 FR, 10 March 2023)
federalregister.gov· Veröffentlicht am 10. März 2023· 1 % der Wertung
The final rule as published: "This rule is effective on September 10, 2024."^[1]

Korrektur vorschlagen

Fehlt etwas oder stimmt etwas nicht? Sag es in deinen eigenen Worten: ein Link, der diesen Pin belegt, ein anderes Start- oder Enddatum und warum, oder eine Angabe, die fehlt oder falsch ist. Die KI prüft es an den Quellen dieses Pins, sucht nach besseren und ergänzt jede Seite, die dich bestätigt. Die eigenen Quellen des Pins zählen weiterhin am meisten.

Kommentare

Thread

Auf diesen Pin antworten

1FDA Rule Requiring Breast Density Notices With Every Mammogram Takes Effect

Gesundheit25.09.2026@HealthDesk
Task Force Tells All US Women to Start Mammograms at 40
United States Preventive Services Task ForceAgency for Healthcare Resource and Quality, 5600, Fishers Lane, Spring Lake Park, Rockville, Montgomery County, Maryland, 20857, United States
Beginnt am 30.04.2024BESTÄTIGT 89 % SICHERHEITvor 2,4 JahrenThe Task Force announcement opens "April 30, 2024 - The U.S. Preventive Services Task Force released today a final recommendation statement on screening for breast cancer^[4]".
The US Preventive Services Task Force finalises its advice that all women get a mammogram every other year from age 40 to 74, lowering the start age from 50.
0.71
Gesundheit25.09.2026@HealthDesk
FDA Approves First HRT Labels Without the Breast Cancer Boxed Warning
U.S. Food and Drug AdministrationMahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United States
Beginnt am 12.02.2026BESTÄTIGT 84 % SICHERHEITvor 225 TagenThe FDA^[1][4] news release is headed "For Immediate Release: February 12, 2026" and says the FDA "has approved drug labeling changes to six menopausal hormone therapy products".
The FDA approves new labels for six menopausal hormone therapy products, one from each class, that drop the cardiovascular, breast cancer and dementia statements from the boxed warning; 29 companies have filed changes.
0.71
Gesundheit25.09.2026@HealthDesk
HHS and FDA Move to Strip Boxed Warnings From Menopause Hormone Therapy
U.S. Food and Drug AdministrationU.S. Department of Health and Human Services, 200, Independence Avenue Southwest, Ward 6, Washington, District of Columbia, 20201, United States
Beginnt am 10.11.2025 16:09BESTÄTIGT 86 % SICHERHEITvor 319 TagenThe FDA^[1][3] news release is headed "For Immediate Release: November 10, 2025" and says Kennedy and Makary "made the announcement at a press conference at HHS"; CBS News' livestream of it began at 16:09 UTC.
At an HHS press conference, Robert F. Kennedy Jr. and FDA Commissioner Marty Makary announce that the FDA will remove the breast cancer, heart disease and dementia boxed warnings that have covered menopausal hormone therapy since the early 2000s.
0.69
Gesundheit25.09.2026@HealthDesk
FDA Decision Due on Roche's Giredestrant for Early Breast Cancer
RocheMahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United States
Beginnt am 30.11.2026GEPLANT 78 % SICHERHEITin 66 TagenRoche's^[1] release says "The FDA is expected to make a decision on the approval by 30 November 2026", the PDUFA goal date set under Priority Review.
The FDA is due to decide by 30 November 2026 whether to approve Roche's giredestrant, an oral SERD that cut the risk of recurrence or death by 30% versus standard hormone therapy in early ER-positive breast cancer.
0.67
Recht25.09.2026@LawDesk
Fifth Circuit Reinstates In-Person Dispensing for Mifepristone
United States Court of Appeals for the Fifth CircuitUnited States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United States
Beginnt am 01.05.2026BESTÄTIGT 82 % SICHERHEITvor 147 TagenThe opinion in No. 26-30203 is stamped "FILED May 1, 2026" and orders that "the motion to stay the 2023 REMS under 5 U.S.C. § 705 pending appeal is GRANTED".^[1]
A Fifth Circuit panel granted Louisiana a stay of the FDA's 2023 mifepristone rules, ending telehealth prescribing and mail or pharmacy dispensing of the abortion pill nationwide until the Supreme Court stepped in.
0.66
Gesundheit23.09.2026@HealthDesk
FDA genehmigt Abbotts Glukose-Keton-Sensor Libre Duo
Abbott Laboratories1360 South Loop Road, Alameda, Alameda County, California, 94502, United States
Beginnt am 25.08.2026BESTÄTIGT 87 % SICHERHEITvor 31 TagenDie Mitteilung trägt die Datumszeile „ABBOTT PARK, Illinois, 25. Aug. 2026“ und besagt, Abbott habe „heute die Genehmigung seines Systems Libre Duo 10 Day durch die US-Arzneimittelbehörde FDA^[2][3] bekanntgegeben“; der De-Novo-Eintrag der FDA nennt dasselbe Entscheidungsdatum, den 25.08.2026.
Die FDA hat Abbotts Libre Duo 10 Day genehmigt, das erste Wearable, das sowohl Glukose als auch Ketone kontinuierlich misst und Menschen mit Diabetes ab 2 Jahren vor einer diabetischen Ketoazidose vor steigenden Ketonwerten warnt.
0.64
Recht25.09.2026@LawDesk
Supreme Court Restores Mail Access to Mifepristone in Louisiana Case
Supreme Court of the United StatesSupreme Court of the United States, 1, 1st Street Northeast, Ward 6, Washington, District of Columbia, 20543, United States
Beginnt am 14.05.2026BESTÄTIGT 84 % SICHERHEITvor 134 TagenThe order in Nos. 25A1207 and 25A1208 is dated "[May 14, 2026]" and says "The applications for stay ... are granted".^[1]
The Supreme Court stayed the Fifth Circuit's order in Louisiana v. FDA, so mifepristone can again be prescribed by telehealth and sent by mail while the case goes on; Justices Thomas and Alito dissented.
0.63
Gesundheit23.09.2026@HealthDesk
Lilly reicht Retatrutid bei der FDA zur Zulassung ein
Eli LillyEli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Beginnt am 31.03.2027GESCHÄTZT3 Monate verspätet77 % SICHERHEITin 187 TagenLilly „plant, Retatrutid anschließend im ersten Quartal 2027 zur Zulassung in den USA einzureichen“ – ein Tag wird nicht genannt, daher liegt der Pin auf dem letzten Tag des ersten Quartals 2027.^[1]
Lilly will den Zulassungsantrag für das Biologikum (BLA) Retatrutid, die Dreifach-Hormon-Spritze gegen Adipositas, die in Phase 3 das Gewicht um bis zu 28,3 Prozent senkte, im ersten Quartal 2027 bei der FDA einreichen, sobald das Datenpaket zur Herstellung vollständig ist.
0.63
Recht25.09.2026@LawDesk
Supreme Court Rejects Challenge to Mifepristone in FDA v. Alliance
Supreme Court of the United StatesSupreme Court of the United States, 1, 1st Street Northeast, Ward 6, Washington, District of Columbia, 20543, United States
Beginnt am 13.06.2024BESTÄTIGT 84 % SICHERHEITvor 2,3 JahrenThe slip opinion in No. 23-235 is headed "Argued March 26, 2024—Decided June 13, 2024".^[1]
A unanimous Supreme Court threw out anti-abortion doctors' challenge to the FDA's rules for the abortion pill mifepristone, holding they had no standing to sue, so mail and telehealth access stayed in place.
0.62
Gesundheit25.09.2026@HealthDesk
FDA Puts a Boxed Liver-Injury Warning on Menopause Drug Veozah
Astellas PharmaMahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United States
Beginnt am 16.12.2024BESTÄTIGT 87 % SICHERHEITvor 1,8 JahrenThe FDA^[1][5] drug safety communication carries the entry "12-16-2024 Update: FDA adds a Boxed Warning, our most prominent warning, to highlight the known risk of rare but serious liver injury".
The FDA adds a boxed warning, its most prominent, to Astellas' hot-flash pill Veozah after a patient suffered serious liver injury within about 40 days of starting it, and orders monthly liver tests for the first months.
0.62
Recht25.09.2026@LawDesk
Fifth Circuit Hears Louisiana's Appeal Against Mail-Order Mifepristone
United States Court of Appeals for the Fifth CircuitUnited States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United States
Beginnt am 09.09.2026BESTÄTIGT 83 % SICHERHEITvor 16 TagenThe court's recording of 26-30203 State of Louisiana v. FDA gives "Hearing Date: Wednesday, September 9, 2026 Courtroom: En Banc Courtroom".^[1]
A Fifth Circuit panel of Judges Richman, Higginson and Douglas heard Louisiana's bid to end telehealth prescribing of mifepristone and pressed the state hard on whether it has standing to sue.
0.61
Gesundheit23.09.2026@HealthDesk
FDA lässt Abbotts Volt-PFA-System gegen Vorhofflimmern zu
Abbott LaboratoriesAbbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Beginnt am 22.12.2025BESTÄTIGT 84 % SICHERHEITvor 277 TagenDie Mitteilung trägt die Ortsangabe "ABBOTT PARK, Ill., 22. Dezember 2025" und besagt, Abbott habe "heute bekannt gegeben", dass die FDA^[5] das Volt PFA System zugelassen hat (der FDA-Eintrag selbst nennt als Entscheidungsdatum den 19.12.2025).
Die FDA hat Abbotts Pulsed-Field-Ablationssystem Volt zugelassen – einen Ballon-im-Korb-Katheter, der kartiert, stimuliert und abladiert – zur Behandlung von paroxysmalem und persistierendem Vorhofflimmern. Grundlage war die VOLT-AF-IDE-Studie mit 392 Patienten an 40 Zentren.
0.61

Ähnliche Pins

Belege 489 % SICHERHEIT

Korrektur vorschlagen

Kommentare

Thread

Ähnliche Pins